



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kilgannon et al. I hereby certify that this paper is being deposited with the United Serial No. 10/025,524 States Postal Service on December 2, 2004 in an envelope addressed to the Filed: December 18, 2001 Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, Title: ICAM-4 Materials and Methods utilizing the "Express Mail Post Office to Addressee" service of the Group Art Unit: 1645 United States Postal Service under Mailing Label No. EV323774642US. Examiner: Patricia Duffy

AMENDMENT AND RESPONSE UNDER 37 C.F.R. §1.111

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY REMARKS

This paper is filed in response to a Final Office Action (hereinafter "the Action") from the U.S. Patent and Trademark Office, mailed June 2, 2004. In the Action, the Examiner maintained the rejection of claim 27 under 35 U.S.C. §112, first paragraph, for assertedly lacking written description and under 35 U.S.C. §103 (a) as assertedly unpatentable in light of Oka et·al., (Neuroscience 35:93-103, 1990) (hereinafter "Oka"), in view of Yoshihara et al,. (Neuron, 12:541-44, 1994) (hereinafter "Yoshihara") and further in view of Goding et al., (Monoclonal Antibodies, 1983 Academic Press Inc.) (hereinafter "Goding"). In view of the following amendments and remarks, reconsideration is respectfully requested.

Remarks begin on page 2 of this paper.

A Notice of Appeal and check in pursuant to 37 CFR 1.17 (b) accompanies this paper.

Sho,